# India Transthyretin Amyloidosis Market

> India Transthyretin Amyloidosis Market Research Report By Disease (Transthyretin (TTR) Familial Amyloid Polyneuropathy), By Gender (Male, Female), By Treatment (Small Molecule Treatment) and By End-User (Ambulatory Surgical Center, Clinics) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.68%
- **2024:** $ 298.98 Million
- **2025:** $ 318.95 Million
- **2035:** $ 608.95 Million
- **Key Players:** Alnylam Pharmaceuticals (US), Pfizer (US), Bristol-Myers Squibb (US), Ionis Pharmaceuticals (US), Eisai Co., Ltd. (JP), Amgen Inc. (US), Teva Pharmaceutical Industries Ltd. (IL), Horizon Therapeutics (IE)

**Report ID:** MRFR/HC/54253-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-transthyretin-amyloidosis-market-56019

---

## Market Summary

## **India Transthyretin Amyloidosis Market Overview**

As per MRFR analysis, the India Transthyretin Amyloidosis Market Size was estimated at 335 (USD Million) in 2023. The India Transthyretin Amyloidosis Market Industry is expected to grow from 365(USD Million) in 2024 to 847 (USD Million) by 2035. The India Transthyretin Amyloidosis Market CAGR (growth rate) is expected to be around 7.953% during the forecast period (2025 - 2035).

### **Key India Transthyretin Amyloidosis Market Trends Highlighted**

Due to the growing awareness and diagnosis of transthyretin amyloidosis (ATTR), a disorder that is frequently underdiagnosed, the India Transthyretin Amyloidosis Market is seeing notable developments. More patients are being seen as a result of healthcare providers detecting ATTR early because of the improved diagnostic facilities and developments in medical imaging technologies. The desire for focused therapies and customized treatment choices for this uncommon ailment is being influenced by the increased awareness among medical professionals and the general public, which is causing a significant change in the paradigm of therapy.

The ongoing efforts to improve healthcare affordability and accessibility are creating new opportunities in the Indian market. Programs to enhance the identification and treatment of uncommon diseases, such as ATTR, are being implemented by the Indian government and other health organizations. Pharmaceutical businesses and healthcare professionals have a greater chance of introducing novel therapies and locally tailored healthcare solutions that specifically address the demands of the Indian people as a result of this. Furthermore, public-private sector partnerships are anticipated to improve this field's research and development activities, meeting unmet medical requirements.

The number of clinical studies in India that are concentrating on new treatments for ATTR has increased recently, which indicates that both domestic and foreign companies are committed to serving the Indian market. New drug approvals for rare diseases are receiving increased support from the regulatory framework, which creates a favorable climate for market participants. Telemedicine and digital health technologies are also becoming more popular because they make it simpler for patients to receive care and consultations from a distance, which enhances patient outcomes and treatment compliance overall.

Overall, these changing patterns and factors are positioning the transthyretin amyloidosis market in India for growth.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

## **India Transthyretin Amyloidosis Market Drivers**

### **Rising Prevalence of Transthyretin Amyloidosis in India**

The increasing incidence of Transthyretin Amyloidosis (ATTR) in India is significantly driving the India Transthyretin Amyloidosis Market Industry. Recent data from the Ministry of Health and Family Welfare reports that approximately 1 in every 1000 individuals over the age of 60 years may be affected by amyloidosis. As India's elderly population is projected to reach 340 million by 2050, this translates to an estimated increase of 340,000 potential cases of Transthyretin Amyloidosis.This increase prompts the need for dedicated healthcare services and treatment options, leading to growth in the overall market.

Prominent organizations such as the All India Institute of Medical Sciences (AIIMS) are actively researching advanced therapies and treatment protocols for ATTR, further promoting market development.

### **Developments in Treatment Options**

The India Transthyretin Amyloidosis Market Industry is experiencing growth driven by advancements in treatment options. The introduction of novel therapeutic agents, such as TTR stabilizers and gene silencing strategies, is enhancing treatment efficacy and patient outcomes. According to ClinicalTrials.gov, there are currently over 15 ongoing clinical trials in India assessing novel therapies for ATTR, indicating a surge in Research and Development (R&D) activities.Organizations like the Indian Council of Medical Research (ICMR) are supporting these trials, highlighting the increasing focus on innovative treatments that can lead to better management of ATTR and serve a growing patient population.

### **Government Initiatives for Rare Disease Management**

The Indian government has been increasingly focusing on policies and initiatives aimed at better management of rare diseases, including Transthyretin Amyloidosis. The National Health Policy of India emphasizes enhancing healthcare access and support systems for patients with rare diseases, encouraging pharmaceutical companies to invest in the India Transthyretin Amyloidosis Market Industry. In 2022, the government established special funds to support research and promote access to medications for patients suffering from rare diseases, which is expected to alleviate treatment costs associated with ATTR.This proactive approach reflects the government's commitment to improving healthcare outcomes and presents significant opportunities for market players.

## **India Transthyretin Amyloidosis Market Segment Insights:**

### **Transthyretin Amyloidosis Market Disease Insights**

The India Transthyretin Amyloidosis Market, particularly within the Disease segment, reflects a growing awareness and need for treatment options pertaining to conditions like Transthyretin (TTR) Familial Amyloid Polyneuropathy. This specific condition is caused by the accumulation of transthyretin proteins, leading to significant neurological damage and various systemic issues. In India, the incidence of TTR Familial Amyloid Polyneuropathy is underscored by a need for precise diagnostic tools and effective therapeutic interventions. As healthcare infrastructure in India advances, there is a noticeable shift towards developing targeted treatments, which is supported by increasing research initiatives and healthcare investments.

This segment has gained importance not only because of the rising patient population but also due to the collaboration between pharmaceutical companies and research institutions that aim to enhance patient care. Moreover, the government policies promoting rare disease management have laid a foundation that promotes therapy accessibility, further driving growth in this segment. The rising prevalence of genetic disorders and a growing understanding of the role of TTR in amyloidosis have also highlighted the significance of effective management strategies.

Given the complexity of symptoms associated with TTR Familial Amyloid Polyneuropathy, early diagnosis, and intervention have become key focus areas for healthcare professionals, thereby positively influencing the India Transthyretin Amyloidosis Market dynamics. As awareness increases in both the medical community and among patients regarding the implications of this condition, it is anticipated that community outreach and education will further refine treatment paradigms, optimizing patient outcomes.

Thus, the Disease segment related to TTR Familial Amyloid Polyneuropathy is poised to play a central role in shaping the future of the India Transthyretin Amyloidosis ecosystem, guided by advancements in science and a commitment to improving healthcare standards across the sector.This continuous growth and nurturing of knowledge around TTR-related disorders reflect both the challenges and opportunities that lie ahead in the management of such complex diseases, reinforcing the need for a strategic approach to market segmentation and targeted therapeutics.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

### **Transthyretin Amyloidosis Market Gender Insights**

The India Transthyretin Amyloidosis Market shows distinctive gender-related patterns, highlighting important trends in the disease's prevalence and management. Males are often observed to have a higher incidence of transthyretin amyloidosis, leading to a notable market interest in male-oriented treatments and therapeutics. However, females also represent a significant portion of the patient population. They are increasingly being targeted for tailored therapies, driven by the growing recognition of their unique health profiles and needs regarding this condition.

This differentiation contributes to the overall market segmentation, which reflects varying treatment approaches and healthcare responses. The trends within the India Transthyretin Amyloidosis Market signify a shift towards more specific and inclusive healthcare solutions. The awareness campaigns and education initiatives aimed at both genders are expected to drive early diagnosis and improve patient outcomes. Additionally, advancements in research targeting gender-specific responses to therapies offer promising avenues for market growth as healthcare providers seek to optimize clinical management strategies for both males and females, ensuring that both groups receive the necessary attention in their treatment paradigms.

### **Transthyretin Amyloidosis Market Treatment Insights**

The Treatment segment of the India Transthyretin Amyloidosis Market focuses on various therapeutic approaches aimed at managing this condition effectively. Among these approaches, Small Molecule Treatment has gained prominence due to its targeted mechanism of action and ability to penetrate cellular membranes, thereby addressing the underlying pathology of transthyretin amyloidosis. This method often offers a favorable safety profile and is associated with improved patient compliance compared to traditional biologics. As awareness around transthyretin amyloidosis increases in India, driven by educational initiatives and advancements in diagnostic techniques, the demand for effective treatments is also expected to rise.

The Indian healthcare ecosystem, supported by government efforts to enhance access to innovative therapies, is paving the way for the introduction of Small Molecule Treatments, which are anticipated to become a significant component of the therapeutic landscape. The increasing focus on precision medicine further underscores the importance of such treatments, as they provide tailored options for patients based on their unique genetic and clinical profiles. Overall, Small Molecule Treatment is positioned to play a critical role in the ongoing evolution of the India Transthyretin Amyloidosis Market, addressing unmet needs and contributing to improved health outcomes.

### **Transthyretin Amyloidosis Market End-User Insights**

The India Transthyretin Amyloidosis Market, under the End-User segmentation, reflects strong demand in various healthcare settings, particularly within Ambulatory Surgical Centers and Clinics. These healthcare environments are pivotal as they facilitate early diagnosis and treatment for patients suffering from transthyretin amyloidosis, thereby improving patient outcomes. Ambulatory Surgical Centers play a vital role in providing specialized, outpatient surgical care with enhanced efficiency, catering to the increasing patient population. Similarly, Clinics offer accessible healthcare options, emphasizing the importance of early intervention and ongoing management of the disease.

The rise in awareness about transthyretin amyloidosis among healthcare professionals and patients is essential, leading to a growing preference for treatment options available in these facilities. As advancements in diagnostics and therapeutic strategies continue to evolve, the role of these End-User categories becomes increasingly significant in the overall landscape of the India Transthyretin Amyloidosis Market, illustrating their critical contribution to disease management and patient care.

## **India Transthyretin Amyloidosis Market Key Players and Competitive Insights:**

The India Transthyretin Amyloidosis Market is experiencing notable growth as awareness of this rare disease increases among healthcare professionals and patients alike. Transthyretin Amyloidosis is a condition caused by the misfolding of the transthyretin protein, leading to the deposition of amyloid fibrils in various organs, including the heart and kidneys, which can cause severe complications. The competitive landscape in this market is characterized by the presence of several pharmaceutical companies engaged in research and development, manufacturing, and distribution of innovative therapies aimed at addressing this condition.

As the demand for effective treatment options surges, companies are focusing on expanding their product pipelines, strengthening collaborations, and enhancing their market strategies to capture a more significant share of this niche market.

Pfizer has established a strong presence in the India Transthyretin Amyloidosis Market through its innovative treatment solutions and extensive distribution networks. The company has been proactive in its clinical research efforts, leading to the development of therapies that target the underlying mechanisms of Transthyretin Amyloidosis. Pfizer's commitment to raising awareness about the disease, along with its established relationships with healthcare providers, has bolstered its position in this market. Additionally, the company’s strong financial backing enables it to invest in further R&D initiatives, thereby enhancing its product offerings.

Pfizer's relentless pursuit of excellence in addressing unmet medical needs positions it favorably against competitors, ensuring that it remains a key player in the treatment landscape for Transthyretin Amyloidosis in India.

Roche has been a significant contender in the India Transthyretin Amyloidosis Market, known for its dedication to delivering key therapeutic solutions for patients suffering from this rare disease. The company offers various products aimed at managing symptoms and improving the quality of life for patients affected by Transthyretin Amyloidosis. Roche’s strong market presence in India is attributed to its robust product lines, which are backed by extensive clinical data supporting their efficacy and safety. Moreover, Roche is actively engaged in partnerships and collaborations to enhance its research capabilities and expand its market reach.

The company has also made strategic acquisitions in the past that have reinforced its portfolio in this therapeutic area. Roche’s focus on innovative approaches and patient-centric strategies solidifies its strengths and enhances its competitive edge in the dynamic landscape of the India Transthyretin Amyloidosis Market.

### **Key Companies in the India Transthyretin Amyloidosis Market Include:**

- Pfizer
- Roche
- Eisai
- Boehringer Ingelheim
- Celgene
- Novartis
- [Amgen](https://www.amgen.com/products)
- Daiichi Sankyo
- Ionis Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Sobi
- AstraZeneca
- Teva Pharmaceutical Industries
- Bristol Myers Squibb
- Alnylam Pharmaceuticals

### **India Transthyretin Amyloidosis Market Industry Developments**

In recent developments within the India Transthyretin Amyloidosis Market, innovative therapies and increased awareness have begun to enhance patient outcomes significantly. Companies such as Pfizer and Alnylam Pharmaceuticals have made notable advancements in their therapeutic offerings, contributing to the growth of this specialized market segment. In November 2022, Eisai announced collaborations to enhance their treatment protocols, further establishing their presence in India. The market is also witnessing growth in valuation as healthcare infrastructure improves, signaling a rising demand for efficient diagnosis and treatment of transthyretin amyloidosis, particularly among older populations in the country.

Additionally, there is reported interest in local partnerships by multinational corporations like Roche and Novartis to cultivate Research and Development initiatives aimed at localizing therapies, ensuring they cater effectively to the Indian demographic. While there haven't been publicly acknowledged mergers or acquisitions affecting the market in the past few months, the push for partnerships remains a vital theme as companies seek to expand their footprint in India. Overall, the progression in therapeutics and rising investments in healthcare infrastructure are shaping a promising future for transthyretin amyloidosis treatment in India.

## **India Transthyretin Amyloidosis Market Segmentation Insights**

### **Transthyretin Amyloidosis Market Disease Outlook**

- Transthyretin (TTR) Familial Amyloid Polyneuropathy

### **Transthyretin Amyloidosis Market Gender Outlook**

- Male
- Female

### **Transthyretin Amyloidosis Market Treatment Outlook**

- Small Molecule Treatment

### **Transthyretin Amyloidosis Market End-User Outlook**

- Ambulatory Surgical Center
- Clinics

## Market Drivers

### Government Initiatives and Support

Government initiatives and support play a pivotal role in shaping the transthyretin amyloidosis market. In India, various health policies aim to enhance the availability of rare disease treatments, including those for transthyretin amyloidosis. The government has been actively promoting research and development in the field of rare diseases, which could lead to the introduction of new therapies. Financial incentives, such as grants and subsidies for pharmaceutical companies, are also being implemented to encourage innovation. Furthermore, public health campaigns aimed at raising awareness about rare diseases are likely to increase patient engagement and drive demand for treatments. As these initiatives gain momentum, the transthyretin amyloidosis market is expected to benefit from increased funding and resources.

### Growing Investment in Biotechnology

The growing investment in biotechnology is a significant driver for the transthyretin amyloidosis market. In India, the biotechnology sector has witnessed substantial growth, with investments reaching approximately $11 billion in recent years. This influx of capital is fostering innovation in drug development, particularly for rare diseases like transthyretin amyloidosis. Biotech firms are increasingly focusing on developing novel therapies, including gene therapies and monoclonal antibodies, which hold promise for treating this condition. As the industry continues to evolve, the transthyretin amyloidosis market is likely to benefit from the introduction of cutting-edge treatments that address unmet medical needs. The synergy between biotechnology advancements and the demand for effective therapies could lead to a robust market landscape.

### Advancements in Diagnostic Technologies

Advancements in diagnostic technologies are significantly impacting the transthyretin amyloidosis market. Enhanced imaging techniques and biomarker identification have improved the accuracy and speed of diagnosis, allowing for earlier intervention. For instance, the introduction of non-invasive imaging modalities, such as cardiac MRI, has revolutionized the detection of transthyretin amyloidosis. This is particularly relevant in India, where timely diagnosis can lead to better patient outcomes. The market for diagnostic tools is projected to grow, with estimates indicating a compound annual growth rate (CAGR) of around 15% over the next five years. As healthcare providers increasingly adopt these advanced technologies, the transthyretin amyloidosis market is likely to expand, driven by the need for effective and efficient diagnostic solutions.

### Rising Patient Advocacy and Support Groups

Rising patient advocacy and support groups are emerging as a vital driver for the transthyretin amyloidosis market. In India, organizations dedicated to raising awareness about rare diseases are gaining traction, providing essential resources and support for patients and their families. These groups play a crucial role in educating the public and healthcare professionals about transthyretin amyloidosis, thereby increasing diagnosis rates and treatment uptake. Furthermore, they often collaborate with pharmaceutical companies and healthcare providers to facilitate access to therapies. As these advocacy efforts continue to grow, they are likely to enhance the visibility of transthyretin amyloidosis, leading to increased demand for treatments and a more informed patient population. This dynamic could significantly influence the market landscape in the coming years.

### Increasing Incidence of Transthyretin Amyloidosis

The rising incidence of transthyretin amyloidosis in India is a crucial driver for the transthyretin amyloidosis market. Recent studies indicate that the prevalence of this condition is increasing, with estimates suggesting that approximately 1 in 100,000 individuals may be affected. This growing patient population necessitates enhanced diagnostic and therapeutic options, thereby stimulating market growth. As awareness of the disease expands among healthcare professionals and the public, more patients are likely to seek medical attention, leading to increased demand for treatments. Furthermore, the aging population in India, which is more susceptible to amyloidosis, contributes to the rising incidence. Consequently, the transthyretin amyloidosis market is poised for growth as healthcare systems adapt to meet the needs of this expanding demographic.

## Future Outlook

The [Transthyretin Amyloidosis Market](https://www.marketresearchfuture.com/reports/transthyretin-amyloidosis-market-6155) is projected to grow at a 6.68% CAGR from 2025 to 2035, driven by increasing awareness, advancements in diagnostics, and innovative therapies.

**New opportunities:**

- Development of targeted gene therapies for transthyretin amyloidosis
- Expansion of telehealth services for remote patient monitoring
- Investment in AI-driven diagnostic tools for early detection

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic investments.

## Segment Insights

### By Drug: Tafamidis (Largest) vs. Inotersen (Fastest-Growing)

In the India transthyretin amyloidosis market, Tafamidis holds the largest market share among drugs, driven by its established efficacy and favorable safety profile. Its popularity stems from growing physician awareness and patient acceptance, making it a go-to option in treatment protocols. In contrast, Inotersen, while smaller in market share, is emerging rapidly, with increasing adoption among healthcare providers due to its novel mechanism of action and the potential for significant patient benefits.

Growth in the drug segment is being propelled by advancements in research and clinical validation of therapies targeting transthyretin amyloidosis. The rising incidence of the disease, coupled with expanding healthcare access and improved diagnosis, are contributing to this upward trend. Additionally, increased focus on innovative treatment options, such as gene silencing therapies like Partisiran, are rejuvenating the market landscape and attracting investment for further development.

Tafamidis (Dominant) vs. Inotersen (Emerging)

Tafamidis remains the dominant player in the drug segment, recognized for its ability to slow the progression of transthyretin amyloidosis and improve quality of life in patients. It is well-integrated into treatment guidelines, supported by substantial clinical evidence. Conversely, Inotersen is regarded as an emerging therapeutic option, leveraging a unique approach of inhibiting transthyretin production. Its rapid uptake in clinical settings reflects the desire for novel treatment modalities that offer hope to patients with limited options. The differential market positions of these drugs highlight the ongoing evolution within the therapeutic landscape, with Tafamidis catering to established treatment needs and Inotersen fulfilling the demand for innovative therapies.

### By Indication: Wild type ATTR Amyloidosis (Largest) vs. Hereditary ATTR Amyloidosis (Fastest-Growing)

In the India transthyretin amyloidosis market, Wild type ATTR Amyloidosis holds the largest share, significantly outpacing Hereditary ATTR Amyloidosis. This dominance can be attributed to the higher prevalence of Wild type ATTR Amyloidosis cases in the aging population, making it a more recognized and treated condition. Hereditary ATTR Amyloidosis, while smaller in market share, is progressively gaining traction due to increasing awareness and advancements in genetic testing that reveal more cases than previously identified.

The growth trends in these segments indicate a robust increase in demand for effective therapies and diagnostic tools for both types. The rising elderly demographic is a key driver for Wild type ATTR Amyloidosis, while the accelerating pace of research and development in targeted treatments fuels the growth of Hereditary ATTR Amyloidosis. Together, these segments are shaping the future of treatment paradigms, showcasing the need for comprehensive care solutions across the board.

Wild type ATTR Amyloidosis (Dominant) vs. Hereditary ATTR Amyloidosis (Emerging)

Wild type ATTR Amyloidosis represents the dominant segment in the India transthyretin amyloidosis market, characterized by its prevalence in older adults and the associated systemic impacts that require immediate medical intervention. The established understanding and therapeutic approaches for this condition have led to a robust treatment framework, enhancing patient outcomes. In contrast, Hereditary ATTR Amyloidosis is an emerging segment that is rapidly gaining recognition due to genetic factors and increased testing capabilities. This segment is defined by its specific genetic mutations, leading to a distinct clinical manifestation that necessitates specialized care. As awareness grows and treatments improve, Hereditary ATTR Amyloidosis is expected to capture a larger market share, reflecting a shift towards more personalized medicine.

### By Distribution Channel: Retail Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing)

In the India transthyretin amyloidosis market, the distribution channels showcase a varied landscape, with retail pharmacies commanding the largest share. These pharmacies are widely available across urban and rural settings, making them the go-to option for patients seeking medication. In contrast, online pharmacies are gaining traction, driven by increasing digital adoption and convenience, marking them as a significant alternative that is rapidly expanding its footprint.

The growth trends in this segment are underpinned by several factors, including an escalating prevalence of transthyretin amyloidosis and a rising demand for accessible treatment options. Retail pharmacies continue to thrive due to their established infrastructure and relationships with healthcare providers. Meanwhile, online pharmacies benefit from the convenience of home delivery and greater accessibility, making them the fastest-growing segment due to the changing consumer preferences towards e-commerce in healthcare.

Retail Pharmacy (Dominant) vs. Online Pharmacy (Emerging)

Retail pharmacies play a dominant role in the India transthyretin amyloidosis market, offering patients personalized services and expert consultations, which enhance the overall medication experience. They often maintain a vast inventory of essential drugs, making them a reliable source for patients. In contrast, online pharmacies are emerging as a formidable player in the market. They capitalize on the shift toward digital platforms, providing a convenient and swift alternative for patients, especially for those in remote areas. The ease of accessing medications through online channels, combined with competitive pricing, positions them as a compelling option for consumers looking for alternatives to traditional retail pharmacies.

### By Treatment: Tafamidis (Largest) vs. RNAi Therapy (Fastest-Growing)

The treatment segment in the India transthyretin amyloidosis market showcases a diverse range of therapeutic options that cater to various patient needs. Currently, Tafamidis stands as the largest segment due to its established efficacy and strong clinical support, capturing substantial market share. Small molecule treatments, including Diflunisal, also maintain considerable presence, while Organ Transplantation represents a critical but niche aspect of treatment options. Additionally, RNAi Therapy is emerging robustly, indicating an evolving landscape of treatment modalities in this sector.

Growth trends within the treatment segment reveal significant advancements in clinical trials and therapeutic innovations. Tafamidis continues to be driven by consistent demand for effective management of transthyretin amyloidosis symptoms. Meanwhile, RNAi Therapy is noted for its rapid growth propelled by increasing investments in biotechnology and a focus on precision medicine. As the market matures, the introduction of novel agents and technological advancements is expected to further enhance treatment landscapes.

Tafamidis (Dominant) vs. RNAi Therapy (Emerging)

Tafamidis has established itself as the dominant player in the treatment landscape for transthyretin amyloidosis due to its solid clinical efficacy and regulatory endorsements, making it a first-line therapy. Its capacity to stabilize transthyretin proteins plays a critical role in alleviating symptoms of the disease. Conversely, RNAi Therapy is an emerging approach that shows promise in gene silencing, aiming to reduce the production of misfolded proteins associated with amyloidosis. This innovative technique is gaining traction, driven by advancements in molecular biology and a tailored therapeutic approach, indicating that while Tafamidis remains the go-to treatment, RNAi Therapy could redefine future treatment paradigms.

## Competitive Benchmarking

The transthyretin amyloidosis market is characterized by a dynamic competitive landscape, driven by increasing awareness and advancements in treatment options. Key players such as Alnylam Pharmaceuticals (US), Pfizer (US), and Bristol-Myers Squibb (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Alnylam Pharmaceuticals (US) focuses on innovation through its RNA interference technology, which has shown promise in treating hereditary transthyretin amyloidosis. Meanwhile, Pfizer (US) emphasizes strategic partnerships to bolster its research capabilities and expand its therapeutic portfolio. Bristol-Myers Squibb (US) is actively pursuing mergers and acquisitions to enhance its pipeline, indicating a robust approach to growth in this niche market. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and collaboration.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for dominance. However, the collective influence of major companies is significant, as they leverage their resources and expertise to shape market dynamics. This competitive structure fosters an environment where innovation is paramount, and companies are incentivized to differentiate themselves through unique offerings.

In October  Alnylam Pharmaceuticals (US) announced a collaboration with a leading Indian biotechnology firm to enhance local clinical trials for its therapies. This strategic move is likely to accelerate the development of treatments tailored to the Indian population, thereby expanding Alnylam's footprint in the region. Such collaborations may also facilitate regulatory approvals, enhancing market access for innovative therapies.

In September  Pfizer (US) launched a new initiative aimed at increasing awareness and education about transthyretin amyloidosis among healthcare professionals in India. This initiative underscores Pfizer's commitment to addressing unmet medical needs and positions the company as a thought leader in the space. By fostering education, Pfizer may enhance its market share and drive demand for its therapies.

In August  Bristol-Myers Squibb (US) completed the acquisition of a smaller biotech firm specializing in novel therapies for amyloidosis. This acquisition is indicative of Bristol-Myers Squibb's aggressive strategy to bolster its pipeline and diversify its offerings. The integration of innovative technologies from the acquired firm could potentially lead to the development of groundbreaking treatments, further solidifying Bristol-Myers Squibb's position in the market.

As of November  current trends in the transthyretin amyloidosis market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on technological advancements and supply chain reliability. This transition may ultimately enhance patient outcomes and foster a more sustainable market environment.

## Recent News & Developments

In recent developments within the India Transthyretin Amyloidosis Market, innovative therapies and increased awareness have begun to enhance patient outcomes significantly. Companies such as Pfizer and Alnylam Pharmaceuticals have made notable advancements in their therapeutic offerings, contributing to the growth of this specialized market segment. In November 2022, Eisai announced collaborations to enhance their treatment protocols, further establishing their presence in India. The market is also witnessing growth in valuation as healthcare infrastructure improves, signaling a rising demand for efficient diagnosis and treatment of transthyretin amyloidosis, particularly among older populations in the country.

Additionally, there is reported interest in local partnerships by multinational corporations like Roche and Novartis to cultivate Research and Development initiatives aimed at localizing therapies, ensuring they cater effectively to the Indian demographic. While there haven't been publicly acknowledged mergers or acquisitions affecting the market in the past few months, the push for partnerships remains a vital theme as companies seek to expand their footprint in India. Overall, the progression in therapeutics and rising investments in healthcare infrastructure are shaping a promising future for transthyretin amyloidosis treatment in India.

## Report Scope

| MARKET SIZE 2024 | 298.98(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 318.95(USD Million) |
| MARKET SIZE 2035 | 608.95(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.68% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Alnylam Pharmaceuticals (US), Pfizer (US), Bristol-Myers Squibb (US), Ionis Pharmaceuticals (US), Eisai Co., Ltd. (JP), Amgen Inc. (US), Teva Pharmaceutical Industries Ltd. (IL), Horizon Therapeutics (IE) |
| Segments Covered | Drug, Indication, Distribution Channel, Treatment |
| Key Market Opportunities | Advancements in gene therapies and novel therapeutics enhance treatment options in the transthyretin amyloidosis market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition in the transthyretin amyloidosis market. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What is the current market valuation of the India transthyretin amyloidosis market?**
A: The market valuation was $298.98 Million in 2024.

**Q: What is the projected market size for the India transthyretin amyloidosis market by 2035?**
A: The projected market size is $608.95 Million by 2035.

**Q: What is the expected CAGR for the India transthyretin amyloidosis market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.68% during the forecast period 2025 - 2035.

**Q: Which companies are the key players in the India transthyretin amyloidosis market?**
A: Key players include Alnylam Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Ionis Pharmaceuticals, Eisai Co., Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Horizon Therapeutics.

**Q: What are the major drug segments in the India transthyretin amyloidosis market?**
A: Major drug segments include Inotersen, Partisiran, Tafamidis, and others, with Tafamidis valued between $120.0 Million and $250.0 Million.

**Q: How does the market perform in terms of indication segments?**
A: The market for Wild type ATTR Amyloidosis is valued between $150.0 Million and $300.0 Million, while Hereditary ATTR Amyloidosis ranges from $148.98 Million to $308.95 Million.

**Q: What distribution channels are utilized in the India transthyretin amyloidosis market?**
A: Distribution channels include retail pharmacy, hospital pharmacy, and online pharmacy, with hospital pharmacy valued between $119.49 Million and $245.34 Million.

**Q: What treatment segments are available in the India transthyretin amyloidosis market?**
A: Treatment segments include small molecule treatment, Tafamidis, Diflunisal, RNAi Therapy, and Organ Transplantation, with Tafamidis valued between $120.0 Million and $250.0 Million.

**Q: What is the significance of Tafamidis in the market?**
A: Tafamidis appears to be a leading treatment option, with a valuation range of $120.0 Million to $250.0 Million.

**Q: How does the market outlook appear for the future?**
A: The market outlook appears positive, with a projected growth to $608.95 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-transthyretin-amyloidosis-market-56019*